SLC5A2 and diabetic kidney disease: Sodium-glucose cotransporter 2 (SGLT2) inhibitor such as dapagliflozin and engagliflozin, is the new strategies for DKD, especially the combination therapy with RAS and SGLT2 inhibitor is effective in controlling the progression of DKD [4].